非布索坦一盒有多少片？

(febuxostat) is a non-purine xanthine oxidase inhibitor developed by Teijin Company of Japan, which can effectively block the formation of uric acid. Compared with allopurinol, a commonly used drug for the treatment of gout, this product has a more significant therapeutic effect. The drug was first registered in the EU in April 2008. It is mainly used clinically to treat gout and has good market prospects. Many patients must be very curious, how many tablets are there in a box of febuxostat?

It is understood that a box of Febuxostat produced by India's Zydus has 30 tablets, and the dosage specification is 80mg*30 tablets/box; while the Febuxostat produced by India's Sun Pharmaceuticals has 100 tablets in a box, and the dosage specification is 40mg*100 tablets/box.

In terms of price, a box of Febuxostat produced by India's Zydus sells for about $80, while a box of Febuxostat produced by India's Sun Pharmaceuticals sells for about $150. The prices of these two versions of the drug are relatively low globally, and the price of Febuxostat (Febuxostat) sold in China has also dropped year-on-year. Patients in need can contact Medical Companion Travel to obtain purchase channels.

The starting dose of febuxostat can be 40 mg/day or 80 mg/day. The specific usage needs to be determined based on the patient's actual situation. For the average patient, after taking 40 mg febuxostat daily for 2 weeks, if the serum uric acid level is still higher than 6 mg/dL, the patient can adjust the dose of the drug to 80 mg/day.

Febuxostat is completely absorbed after oral administration, with a bioavailability of approximately 85%, a peak time of approximately 1 hour, and a half-life of 5 to 8 hours. Food and antacids have no significant effect on the absorption of febuxostat. The drug is metabolized by the liver P450 enzyme system in the body and excreted by the kidneys. <5% is excreted unchanged in the urine. According to reports in the literature, mild to moderate liver function impairment and mild to moderate renal function impairment have no significant impact on the pharmacokinetic parameters of (febuxostat).

Recommended hot articles: /newsDetail/79061.html